These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38663957)

  • 1. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
    Tripathi P; Kumari R; Pathak R
    Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors.
    Sahu P; Mitra A; Ganguly A
    Int Rev Cell Mol Biol; 2024; 386():167-222. PubMed ID: 38782499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
    Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
    Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
    Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the undruggable oncogenic KRAS: the dawn of hope.
    Asimgil H; Ertetik U; Çevik NC; Ekizce M; Doğruöz A; Gökalp M; Arık-Sever E; Istvanffy R; Friess H; Ceyhan GO; Demir IE
    JCI Insight; 2022 Jan; 7(1):. PubMed ID: 35014625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging KRAS: current perspectives and state-of-art review.
    Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
    J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the MAPK Pathway in KRAS-Driven Tumors.
    Drosten M; Barbacid M
    Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting
    Uras IZ; Moll HP; Casanova E
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
    Liu H; Qian F
    Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
    Salgia R; Pharaon R; Mambetsariev I; Nam A; Sattler M
    Cell Rep Med; 2021 Jan; 2(1):100186. PubMed ID: 33521700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.